379
Views
14
CrossRef citations to date
0
Altmetric
Infectious Disease

Identification of congenital CMV cases in administrative databases and implications for monitoring prevalence, healthcare utilization, and costs

ORCID Icon, ORCID Icon & ORCID Icon
Pages 769-779 | Received 09 Jul 2020, Accepted 11 Feb 2021, Published online: 04 Mar 2021

References

  • Fowler KB, Ross SA, Shimamura M, et al. Racial and ethnic differences in the prevalence of congenital cytomegalovirus infection. J Pediatr. 2018;200:196–201 e191.
  • Yamaguchi A, Oh-Ishi T, Arai T, et al. Screening for seemingly healthy newborns with congenital cytomegalovirus infection by quantitative real-time polymerase chain reaction using newborn urine: an observational study. BMJ Open. 2017;7(1):e013810.
  • Inagaki K, Blackshear C, Palmer A, et al. Risk factors, geographic distribution, and healthcare burden of symptomatic congenital cytomegalovirus infection in the United States: analysis of a nationally representative database, 2000–2012. J Pediatr. 2018;199:118–123 e111.
  • Dreher AM, Arora N, Fowler KB, et al. Spectrum of disease and outcome in children with symptomatic congenital cytomegalovirus infection. J Pediatr. 2014;164(4):855–859.
  • Goderis J, De Leenheer E, Smets K, et al. Hearing loss and congenital CMV infection: a systematic review. Pediatrics. 2014;134(5):972–982.
  • Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol. 2007;17(5):355–363.
  • Rawlinson WD, Boppana SB, Fowler KB, et al. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. Lancet Infect Dis. 2017;17(6):e177–e188.
  • Leung J, Cannon MJ, Grosse SD, et al. Laboratory testing and diagnostic coding for cytomegalovirus among privately insured infants in the United States: a retrospective study using administrative claims data. BMC Pediatr. 2013;13:90.
  • Sorichetti B, Goshen O, Pauwels J, et al. Symptomatic congenital cytomegalovirus infection Is underdiagnosed in British Columbia. J Pediatr. 2016;169:316–317.
  • Tran C, Bennett MV, Gould JB, et al. Cytomegalovirus infection among infants in neonatal intensive care units, California, 2005 to 2016. Am J Perinatol. 2020;37(02):146–150.
  • Luck SE, Wieringa JW, Blazquez-Gamero D, et al. Congenital cytomegalovirus: a European expert consensus statement on diagnosis and management. Pediatr Infect Dis J. 2017;36(12):1205–1213.
  • Smiljkovic M, Le Meur JB, Malette B, et al. Blood viral load in the diagnostic workup of congenital cytomegalovirus infection. J Clin Virol. 2020;122:104231.
  • Bartlett AW, Hall BM, Palasanthiran P, et al. Recognition, treatment, and sequelae of congenital cytomegalovirus in Australia: an observational study. J Clin Virol. 2018;108:121–125.
  • Cannon MJ, Grosse SD, Fowler KB. The epidemiology and public health impact of congenital cytomegalovirus infection. In: Reddehase M, editor. Cytomegaloviruses: from molecular pathogenesis to intervention. Vol. 2. Norfolk (UK): Caister Academic Press; 2013. p. 26–48.
  • Lanzieri TM, Leung J, Caviness AC, et al. Long-term outcomes of children with symptomatic congenital cytomegalovirus disease. J Perinatol. 2017;37(7):875–880.
  • Lanzieri TM, Chung W, Flores M, et al. Hearing loss in children with asymptomatic congenital cytomegalovirus infection. Pediatrics. 2017;139(3):e20162610.
  • Grosse SD, Ross DS, Dollard SC. Congenital cytomegalovirus (CMV) infection as a cause of permanent bilateral hearing loss: a quantitative assessment. J Clin Virol. 2008;41(2):57–62.
  • Walter E, Brennig C, Schöllbauer V, et al. How to save money: congenital CMV infection and the economy. In: Halwachs-Baumann G, editor. Congenital Cytomegalovirus Infection. 2nd ed. Cham, Switzerland: Springer; 2018. p. 121–144.
  • Retzler J, Hex N, Bartlett C, et al. Economic cost of congenital CMV in the UK. Arch Dis Child. 2019;104(6):559–563.
  • Korndewal MJ, Weltevrede M, van den Akker-van Marle ME, et al. Healthcare costs attributable to congenital cytomegalovirus infection. Arch Dis Child. 2018;103(5):452–457.
  • Fowler KB, Boppana SB. Congenital cytomegalovirus infection. Semin Perinatol. 2018;42(3):149–154.
  • Grosse SD, Dollard SC, Ortega-Sanchez IR. Economic assessments of the burden of congenital cytomegalovirus infection and the cost-effectiveness of prevention strategies. Semin Perinatol. 2021. DOI:https://doi.org/10.1016/j.semperi.2021.151393
  • Lucas A, Sinha A, Fowler KB, et al. A framework for assessing the lifetime economic burden of congenital cytomegalovirus in the United States. Cost Eff Resour Alloc. 2019;17(1):21.
  • Lopez AS, Ortega-Sanchez IR, Bialek SR. Congenital cytomegalovirus-related hospitalizations in infants <1 year of age, United States, 1997–2009. Pediatr Infect Dis J. 2014;33(11):1119–1123.
  • Candrilli S, Trantham L. The economic burden of congenital cytomegalovirus-related hospitalizations in the United States. Val Health. 2017;20(9):A784–A785.
  • Meyers J, Sinha A, Samant S, et al. The economic burden of congenital cytomegalovirus disease in the first year of life: a retrospective analysis of health insurance claims data in the United States. Clin Ther. 2019;41(6):1040–1056 e1043.
  • Berry JG, Hall M, Neff J, et al. Children with medical complexity and Medicaid: spending and cost savings. Health Aff (Millwood). 2014;33(12):2199–2206.
  • Howard SW, Zhang Z, Buchanan P, et al. The effect of a comprehensive care transition model on cost and utilization for medically complex children with cerebral palsy. J Pediatr Health Care. 2017;31(6):634–647.
  • Kadambari S, Pollard AJ, Goldacre MJ, et al. Congenital viral infections in England over five decades: a population-based observational study. Lancet Infect Dis. 2020;20(2):220–229.
  • Seale H, Booy R, MacIntyre CR. Trends in hospitalizations for diagnosed congenital cytomegalovirus in infants and children in Australia. BMC Pediatr. 2009;9:7.
  • Leung J, Dollard SC, Grosse SD, et al. Valganciclovir use among commercially and Medicaid-insured infants with congenital CMV infection in the United States, 2009–2015. Clin Ther. 2018;40(3):430–439 e431.
  • Leung J, Kennedy JL, Haberling DL, et al. Congenital CMV-coded diagnosis among American Indian and Alaska Native infants in the United States, 2000–2017. J Immigrant Minority Health. 2020;22(5):1101–1104.
  • Lin C, Tomio J, Tanaka H, et al. Diagnosis and medical care for congenital cytomegalovirus infection: An observational study using claims data in Japan, 2010 to 2017. Medicine (Baltimore). 2020;99(10):e19419.
  • Messinger CJ, Lipsitch M, Bateman BT, et al. Association between congenital cytomegalovirus and the prevalence at birth of microcephaly in the United States. JAMA Pediatr. 2020;174(12):1159–1167.
  • Tanaka S, Seto K, Kawakami K. Pharmacoepidemiology in Japan: medical databases and research achievements. J Pharm Health Care Sci. 2015;1(1):1–4.
  • Worth RM, Mytinger RE. Medical insurance claims as a source of data for research: accuracy of diagnostic coding. Hawaii Med J. 1996;55(1):9–11.
  • Andrade SE, Scott PE, Davis RL, et al. Validity of health plan and birth certificate data for pregnancy research. Pharmacoepidemiol Drug Saf. 2013;22(1):7–15.
  • Metcalfe A, Sibbald B, Lowry RB, et al. Validation of congenital anomaly coding in Canada’s administrative databases compared with a congenital anomaly registry. Birth Defects Res A Clin Mol Teratol. 2014;100(2):59–66.
  • Sickbert-Bennett EE, Weber DJ, Poole C, et al. Completeness of communicable disease reporting, North Carolina, USA, 1995–1997 and 2000–2006. Emerg Infect Dis. 2011;17(1):23–29.
  • Lanes S, Brown JS, Haynes K, et al. Identifying health outcomes in healthcare databases. Pharmacoepidemiol Drug Saf. 2015;24(10):1009–1016.
  • McPheeters ML, Sathe NA, Jerome RN, et al. Methods for systematic reviews of administrative database studies capturing health outcomes of interest. Vaccine. 2013;31 Suppl 10(10):K2–K6.
  • Benchimol EI, Manuel DG, To T, et al. Development and use of reporting guidelines for assessing the quality of validation studies of health administrative data. J Clin Epidemiol. 2011;64(8):821–829.
  • Ronald LA, Ling DI, FitzGerald JM, et al. Validated methods for identifying tuberculosis patients in health administrative databases: systematic review. Int J Tuberc Lung Dis. 2017;21(5):517–522.
  • Pisesky A, Benchimol EI, Wong CA, et al. Incidence of hospitalization for respiratory syncytial virus infection amongst children in Ontario, Canada: a population-based study using validated health administrative data. PLoS One. 2016;11(3):e0150416.
  • Fell DB, Platt RW, Basso O, et al. The relationship between 2009 pandemic H1N1 influenza during pregnancy and preterm birth: a population-based cohort study. Epidemiology. 2018;29(1):107–116.
  • Weimer KED, Kelly MS, Permar SR, et al. Association of adverse hearing, growth, and discharge age outcomes with postnatal cytomegalovirus infection in infants with very low birth weight. JAMA Pediatr. 2020;174(2):133–140.
  • Grosse SD, Do TQN, Vu M, et al. Healthcare expenditures for privately insured US patients with cystic fibrosis, 2010–2016. Pediatr Pulmonol. 2018;53(12):1611–1618.
  • Grosse SD, Waitzman NJ, Yang N, et al. Employer-sponsored plan expenditures for infants born preterm. Pediatrics. 2017;140(4):e20171078.
  • Mehrotra A, Hussey P. Including physicians in bundled hospital care payments: time to revisit an old idea? JAMA. 2015;313(19):1907–1908.
  • Hamavid H, Birger M, Bulchis AG, et al. Assessing the complex and evolving relationship between charges and payments in US hospitals: 1996–2012. PLoS One. 2016;11(7):e0157912.
  • Agency for Healthcare Research and Quality. HCUPnet. Healthcare Cost and Utilization Project. 2020; [cited 2020 Oct 1]. https://hcupnet.ahrq.gov/.
  • Peterson C, Xu L, Florence C, et al. Professional fee ratios for US hospital discharge data. Med Care. 2015;53(10):840–849.
  • Arth AC, Tinker SC, Simeone RM, et al. Inpatient hospitalization costs associated with birth defects among persons of all ages - United States, 2013. MMWR Morb Mortal Wkly Rep. 2017;66(2):41–46.
  • Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Pharmacoeconomics. 2013;31(5):361–367.
  • Dunn A, Grosse SD, Zuvekas SH. Adjusting health expenditures for inflation: a review of measures for health services research in the United States. Health Serv Res. 2018;53(1):175–196.
  • Biener AI, Selden TM. Public and private payments for physician office visits. Health Aff (Millwood). 2017;36(12):2160–2164.
  • Selden TM. Differences between public and private hospital payment rates narrowed, 2012–16. Health Aff (Millwood). 2020;39(1):94–99.
  • Wang L, Mandell DS, Lawer L, et al. Healthcare service use and costs for autism spectrum disorder: a comparison between Medicaid and private insurance. J Autism Dev Disord. 2013;43(5):1057–1064.
  • Amendah DD, Mvundura M, Kavanagh PL, et al. Sickle cell disease-related pediatric medical expenditures in the U.S. Am J Prev Med. 2010;38(4 Suppl):S550–S556.
  • Buhi ER, Goodson P, Neilands TB. Out of sight, not out of mind: Strategies for handling missing data. Am J Health Behav. 2008;32(1):83–92.
  • Weichle T, Hynes DM, Durazo-Arvizu R, et al. Impact of alternative approaches to assess outlying and influential observations on health care costs. Springerplus. 2013;2(1):614.
  • Li R, Simmons KB, Bertolli J, et al. Cost-effectiveness of increasing access to contraception during the Zika virus outbreak, Puerto Rico, 2016. Emerg Infect Dis. 2017;23(1):74–82.
  • Lee DW, Meyer JW, Clouse J. Implications of controlling for comorbid conditions in cost-of-illness estimates: a case study of osteoarthritis from a managed care system perspective. Value Health. 2001;4(4):329–334.
  • Korndewal MJ, Oudesluys-Murphy AM, Kroes ACM, et al. Long-term impairment attributable to congenital cytomegalovirus infection: a retrospective cohort study. Dev Med Child Neurol. 2017;59(12):1261–1268.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.